Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK's RSV Vaccine (GSK3844766A) in Young and Older Adults
NCT03814590Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of respiratory syncytial virus vaccine, recombinant, adjuvanted in respiratory syncytial virus infection (RSV) (14 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any Solicited Local Symptoms After First Vaccination Dose, Number of Subjects With Any Solicited Local Symptoms After Second Vaccination Dose and 7 more. Started Jan 2019; status: completed.
02
Drugs
respiratory syncytial virus vaccine, recombinant, adjuvanted
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03814590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814590.